UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. PRIM
2. ABBV
3. IBM
4. META
5. NAVN
6. DFTX
7. CNC
8. KFY
9. SPY
10. MU

Go back to UPDATE: Syndax Pharmaceuticals (SNDX) Tops Q4 EPS by 11c; Encore 601 Refractory Melanoma Cohort to Proceed to Second Stage of Phase 2

Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update

March 2, 2017 4:05 PM EST

Encore 601 refractory melanoma cohort to proceed to second stage of Phase 2; pre-specified objective response criteria satisfied

Enrollment of the first stage of both NSCLC cohorts completed; decision whether to progress each cohort into the second stage of Phase 2 anticipated in 1H2017

WALTHAM, Mass., March 02, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today reported its financial results for the fourth quarter... More